Company News - Great Wall Motors (02333.HK) expects a total revenue of RMB 222.79 billion in 2025, representing a year-on-year increase of 10.19%. However, net profit is projected to decline by 21.71% to RMB 9.912 billion due to increased investments in new user channels and marketing for new models and technologies [2] - China Southern Airlines (01055.HK) anticipates turning a profit in 2025, with net profit expected to be between RMB 800 million and RMB 1 billion [2] - CICC (03908.HK) forecasts a net profit of RMB 8.542 billion to RMB 10.535 billion in 2025, reflecting a year-on-year increase of 50% to 85% [3] - Datang Power (00991.HK) projects a net profit of approximately RMB 6.8 billion to RMB 7.8 billion in 2025, indicating a year-on-year increase of about 51% to 73% [4] - Rongchang Bio (09995.HK) expects 2025 revenue of approximately RMB 3.25 billion, a year-on-year increase of about 89%, and a net profit of around RMB 716 million, achieving profitability [4] - Haijia Medical (06078.HK) anticipates revenue of approximately RMB 4.0 billion to RMB 4.05 billion in 2025, a year-on-year decrease of about 9% to 10%, with net profit expected to decline by 66% to 76% to around RMB 140 million to RMB 200 million [4] - Junshi Biosciences (01877.HK) expects 2025 revenue of around RMB 2.5 billion, a year-on-year increase of approximately 28.32%, with a net loss of about RMB 873 million, a reduction of 31.85% compared to the previous year [4] - Kaisa New Energy (01108.HK) issued a profit warning, expecting a year-on-year increase in net loss of approximately RMB 90.07 million to RMB 290 million [4] - Xingye Alloy (00505.HK) issued a profit warning, anticipating a year-on-year decrease in profit attributable to equity shareholders of about 50% [4] - Fudan Zhangjiang (01349.HK) issued a profit warning, expecting a net loss of approximately RMB 120 million to RMB 180 million in 2025 [4] - Chenming Paper (01812.HK) issued a profit warning, expecting a net loss of RMB 8.2 billion to RMB 8.8 billion, a significant increase compared to the previous year [5] - Tianqi Lithium (09696.HK) has commenced production of the first batch of standard chemical-grade lithium concentrate products from its third-phase expansion project [6] Financing and Buyback Activities - Xiaomi Group-W (01810.HK) repurchased approximately 4.2 million shares for about HKD 150 million, with repurchase prices ranging from HKD 35.13 to HKD 42.50 [10] - Vitasoy International (00345.HK) repurchased shares worth HKD 24.37 million, acquiring 3.492 million shares at prices between HKD 6.9 and HKD 7 [11] - Yujian Xiaomian (02408.HK) plans to repurchase up to HKD 100 million of H-shares [12] - Nanshan Aluminum International (02610.HK) completed a placement of 31 million shares, raising approximately HKD 1.987 billion [12]

Core Viewpoint - Haijia Medical (06078) anticipates a decline in revenue and net profit for 2025, primarily due to goodwill impairment and increased operational costs [1] Financial Projections - The company expects revenue for 2025 to be approximately RMB 4.0–4.5 billion, representing a year-on-year decrease of about 9% to 10% [1] - Net profit is projected to be around RMB 140–200 million, reflecting a significant year-on-year decline of approximately 66% to 76% [1] - Adjusted net profit is estimated at RMB 450–490 million, indicating a year-on-year decrease of about 19% to 25% [1] - Cash generated from operating activities is expected to be between RMB 940–1,000 million, showing a year-on-year increase of approximately 33% to 41% [1] Factors Influencing Performance - The decline in revenue, net profit, and adjusted net profit is attributed to industry and macroeconomic impacts, as well as increased startup costs and depreciation expenses from newly opened hospitals [1] - The anticipated drop in net profit for the year ending December 31, 2025, is also significantly influenced by the goodwill impairment provision related to Etern Group Ltd. [1] - The company has conducted a careful assessment of its operational and financial performance, along with future business prospects, to determine the necessity and amount of the impairment and provision [1]

Core Viewpoint - The company, Haijia Medical (06078), anticipates a revenue decline of approximately 9% to 10% for 2025, with projected revenues between RMB 4.0 billion and 4.05 billion [1] Financial Performance Summary - The expected net profit for 2025 is projected to be between RMB 1.4 billion and 2.0 billion, reflecting a significant decrease of approximately 66% to 76% primarily due to goodwill impairment [1] - Adjusted net profit is forecasted to be between RMB 4.5 billion and 4.9 billion, indicating a year-on-year decline of about 19% to 25% [1] - The net cash generated from operating activities is expected to be between RMB 9.4 billion and 10.0 billion, showing an increase of approximately 33% to 41% year-on-year [1] Factors Influencing Performance - The decline in revenue, net profit, and adjusted net profit is attributed to industry and macroeconomic impacts, as well as increased startup costs and depreciation expenses from newly opened hospitals [1] - The net profit decrease for the year ending December 31, 2025, is also significantly influenced by the goodwill impairment provision related to Etern Group Ltd. [1] - The company has conducted a careful assessment of its operational and financial performance, as well as the future prospects of its business, to determine the necessity and amount of the impairment and provision [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Hygeia Healthcare Holdings Co., Limited （ 於 公 司 ） 海 吉 亞 醫 療 控 股 有 限 公 司 開 曼 群 島 註 冊 成 立 的 有 限 （股 份 代 號：6078） 盈利預警 海吉亞醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571 章《證券及期貨條例》第XIVA部項下之內幕消息條文（定義見上市規則）作出本 公告。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資 者，基於對本集團截至二零二五年十二月三十一日止年度未經審核綜合管理 賬目（按國際財務報告準則(IFRS)編製）的初步評估及董事會目前可得資料，預 計： – 1 – 股東及本公司潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 海吉亞醫療控股有限公司 主席 (i ...

Core Viewpoint - Southbound funds have reduced their holdings in Haijia Medical (06078.HK) by 168,400 shares on January 28, with a total net reduction of 2.18 million shares over the past five trading days and 8.97 million shares over the last twenty trading days [1] Group 1: Southbound Fund Activity - Southbound funds have reduced their holdings in Haijia Medical for 4 out of the last 5 trading days, totaling a net reduction of 218,000 shares [1] - Over the past 20 trading days, there have been 16 days of reductions, with a cumulative net decrease of 8.97 million shares [1] - Currently, southbound funds hold 202 million shares of Haijia Medical, representing 32.62% of the company's total issued ordinary shares [1] Group 2: Company Overview - Haijia Medical Holdings Limited is primarily an investment holding company that provides medical services [1] - The company operates through two business segments, with the hospital business segment focusing on comprehensive cancer diagnosis and treatment services [1] - The other business segment is involved in various other operations, primarily within the domestic market [1]

Core Viewpoint - Southbound funds have reduced their holdings in Haijia Medical (06078.HK) by 511,400 shares on January 9, indicating a trend of net selling over recent trading days [1] Group 1: Shareholding Changes - In the last 5 trading days, southbound funds have net sold a total of 2,574,400 shares of Haijia Medical [1] - Over the past 20 trading days, there have been 14 days of net selling, with a cumulative reduction of 4,068,600 shares [1] - Currently, southbound funds hold 206 million shares of Haijia Medical, representing 33.33% of the company's total issued ordinary shares [1] Group 2: Company Overview - Haijia Medical Holdings Limited is primarily an investment holding company that provides medical services [1] - The company operates through two business segments: the hospital business segment focuses on comprehensive cancer diagnosis and treatment services, including multiple oncology medical services such as radiotherapy, chemotherapy, surgery, and targeted therapy [1] - The other business segment is engaged in various other operations, with the company primarily conducting its business in the domestic market [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 公司名稱: 海吉亞醫療控股有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Hai Ji Ya Medical (06078.HK) by 617,200 shares on January 2, with a total net reduction of 4,525,200 shares over the past five trading days [1] - Over the last 20 trading days, there have been 11 days of net reductions by southbound funds, totaling 1,763,000 shares [1] - As of now, southbound funds hold 208 million shares of Hai Ji Ya Medical, which represents 33.64% of the company's total issued ordinary shares [1] Group 2 - Hai Ji Ya Medical Holdings Limited is primarily an investment holding company that provides medical services [1] - The company operates through two business segments, with the hospital business segment focusing on comprehensive cancer diagnosis and treatment services, including radiation therapy, chemotherapy, surgery, and targeted therapy [1] - The other business segment is engaged in various other operations, with the company primarily conducting its business in the domestic market [1]

Group 1 - The company, Haijia Medical (06078.HK), announced a share buyback on December 31, spending HKD 1.242 million to repurchase 100,000 shares at a price of HKD 12.42 per share [1]

Core Viewpoint - Haijia Medical (06078) announced a share buyback plan, intending to repurchase 100,000 shares at a cost of HKD 1.242 million by December 31, 2025 [1] Group 1 - The company will spend HKD 1.242 million for the buyback [1] - The buyback involves repurchasing 100,000 shares [1] - The completion date for the buyback is set for December 31, 2025 [1]